跳轉至內容
Merck
全部照片(1)

文件

PHR1624

Supelco

顺铂

Pharmaceutical Secondary Standard; Certified Reference Material

同義詞:

顺铂, 顺-二氯二氨基铂(II), 顺式-二胺二氯铂, 顺氯氨铂

登入查看組織和合約定價


About This Item

線性公式:
Pt(NH3)2Cl2
CAS號碼:
分子量::
300.05
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material
pharmaceutical secondary standard

品質等級

agency

traceable to Ph. Eur. C2210000
traceable to USP 1134357

API 家族

cisplatin

CofA

current certificate can be downloaded

包裝

pkg of 200 mg

技術

HPLC: suitable
gas chromatography (GC): suitable

mp

270 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-30°C

SMILES 字串

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI 密鑰

LXZZYRPGZAFOLE-UHFFFAOYSA-L

尋找類似的產品? 前往 產品比較指南

一般說明

用于质量控制的制药二级标准品,为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。
顺铂是抗肿瘤药,用于治疗各种恶性肿瘤患者。

應用

这些二级标准品是经过检验的认证标准物质(CRM)。它们适用于多种分析应用,包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。
顺铂可用作分析参考标准品,通过高效液相色谱测定法测定血浆、癌细胞和肿瘤样品中的分析物。

生化/生理作用

强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物,诱导链内交联。

分析報告

这些二级标准提供了有效的美国药典、欧洲药典和英国药典一级标准的多重可追溯性。

其他說明

该认证参考物质(CRM)根据ISO 17034ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在分析证书上找到。

腳註

要查看该材料的分析证书示例,请在下面的栏位中输入LRAB7778。这只是一个示例证书,可能不是您收到的批次。

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
Adrián E Granada et al.
Molecular biology of the cell, 31(8), 845-857 (2020-02-13)
DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging
Jessica M Rusert et al.
Cancer research, 80(23), 5393-5407 (2020-10-14)
Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務